324 related articles for article (PubMed ID: 10516002)
1. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.
Trkola A; Matthews J; Gordon C; Ketas T; Moore JP
J Virol; 1999 Nov; 73(11):8966-74. PubMed ID: 10516002
[TBL] [Abstract][Full Text] [Related]
2. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
Montefiori DC; Collman RG; Fouts TR; Zhou JY; Bilska M; Hoxie JA; Moore JP; Bolognesi DP
J Virol; 1998 Mar; 72(3):1886-93. PubMed ID: 9499040
[TBL] [Abstract][Full Text] [Related]
3. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.
Spenlehauer C; Gordon CA; Trkola A; Moore JP
Virology; 2001 Feb; 280(2):292-300. PubMed ID: 11162843
[TBL] [Abstract][Full Text] [Related]
4. A new cell line-based neutralization assay for primary HIV type 1 isolates.
Shi Y; Albert J; Francis G; Holmes H; Fenyö EM
AIDS Res Hum Retroviruses; 2002 Sep; 18(13):957-67. PubMed ID: 12230938
[TBL] [Abstract][Full Text] [Related]
5. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
Trkola A; Ketas T; Kewalramani VN; Endorf F; Binley JM; Katinger H; Robinson J; Littman DR; Moore JP
J Virol; 1998 Mar; 72(3):1876-85. PubMed ID: 9499039
[TBL] [Abstract][Full Text] [Related]
6. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.
Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H
J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675
[TBL] [Abstract][Full Text] [Related]
7. Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals.
Nokta MA; Li XD; Nichols J; Mallen M; Pou A; Asmuth D; Pollard RB
AIDS; 2001 Jan; 15(2):161-9. PubMed ID: 11216923
[TBL] [Abstract][Full Text] [Related]
8. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
[TBL] [Abstract][Full Text] [Related]
9. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
Bunnik EM; Quakkelaar ED; van Nuenen AC; Boeser-Nunnink B; Schuitemaker H
J Virol; 2007 Jan; 81(2):525-31. PubMed ID: 17079299
[TBL] [Abstract][Full Text] [Related]
10. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
Cecilia D; KewalRamani VN; O'Leary J; Volsky B; Nyambi P; Burda S; Xu S; Littman DR; Zolla-Pazner S
J Virol; 1998 Sep; 72(9):6988-96. PubMed ID: 9696790
[TBL] [Abstract][Full Text] [Related]
11. CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates.
Mörner A; Björndal A; Leandersson AC; Albert J; Björling E; Jansson M
AIDS Res Hum Retroviruses; 2002 Feb; 18(3):193-200. PubMed ID: 11839153
[TBL] [Abstract][Full Text] [Related]
12. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.
Lee S; Lapham CK; Chen H; King L; Manischewitz J; Romantseva T; Mostowski H; Stantchev TS; Broder CC; Golding H
J Virol; 2000 Jun; 74(11):5016-23. PubMed ID: 10799575
[TBL] [Abstract][Full Text] [Related]
13. Association of neutralization sensitivity of HIV-1 primary isolates with biological properties of isolates from HIV-1 infected Chinese individuals.
Hei FX; Tang HL; Hong KX; Chen JP; Peng H; Yuan L; Xu JQ; Shao YM
Biomed Environ Sci; 2005 Apr; 18(2):128-36. PubMed ID: 16001833
[TBL] [Abstract][Full Text] [Related]
14. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
15. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
[TBL] [Abstract][Full Text] [Related]
16. Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
König RR; Flory E; Steidl S; Neumann J; Coulibaly C; Holznagel E; Holzammer S; Norley S; Cichutek K
J Virol; 2002 Nov; 76(21):10627-36. PubMed ID: 12368305
[TBL] [Abstract][Full Text] [Related]
17. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.
Dreyer K; Kallas EG; Planelles V; Montefiori D; McDermott MP; Hasan MS; Evans TG
AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1563-71. PubMed ID: 10580407
[TBL] [Abstract][Full Text] [Related]
18. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
19. Selective HIV-1-induced downmodulation of CD4 and coreceptors.
Chenine AL; Sattentau Q; Moulard M
Arch Virol; 2000; 145(3):455-71. PubMed ID: 10795515
[TBL] [Abstract][Full Text] [Related]
20. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
Painter SL; Biek R; Holley DC; Poss M
J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
